Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30

$0.63−0.05 (-7.99%)

Close on Nov 13, 2026Market cap $20.45MP/E –Yield –

Celularity price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Celularity's price to sales ratio was 1.2× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.5× to 68.1×, with a median of 2.6×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	1.2×	+0.4
2025	Dec 31, 2025	0.8×	−0.2
2024	Dec 31, 2024	0.9×	−2.3
2023	Dec 29, 2023	3.2×	−6.7
2022	Dec 30, 2022	10.0×	−22.1
2021	Dec 31, 2021	32.1×	–

Where these numbers come from

Parsed from the XBRL in Celularity's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jul 30, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CELU.

Compare: CELU vs CAPR · CELU vs PRQR · CELU vs JAGX · CELU vs EMMA · CELU vs CASIF

Revenue growth-58.1% · median 73.5%

Gross margin19.2% · median 88.0%

Operating margin-264.3% · median -93.1%

Net margin-245.7% · median -133.9%

Company	Revenue	Growth
JAGX	$27.82M	+135.5%
CELU	$18.67M	-58.1%
PRQR	€18.36M	+11.4%
EMMA	$15.53M	–
CAPR	–	–
CASIF	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 115
Held by institutions: 6.8%
Auditor: EisnerAmper LLP
SEC CIK: 1752828

Advertisement
300 × 250

See a number that looks wrong?